These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

309 related items for PubMed ID: 38701084

  • 1. Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis.
    James LP, Klaassen F, Sweeney S, Furin J, Franke MF, Yaesoubi R, Chesov D, Ciobanu N, Codreanu A, Crudu V, Cohen T, Menzies NA.
    PLoS Med; 2024 May; 21(5):e1004401. PubMed ID: 38701084
    [Abstract] [Full Text] [Related]

  • 2. Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe.
    Günther G, Guglielmetti L, Kherabi Y, Duarte R, Lange C, Tuberculosis Network European Trials group.
    Clin Microbiol Infect; 2024 Sep; 30(9):1197.e1-1197.e4. PubMed ID: 38490355
    [Abstract] [Full Text] [Related]

  • 3. Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial.
    Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, Moodliar R, Dodd M, Solodovnikova V, Liverko I, Rajaram S, Rassool M, McHugh T, Spigelman M, Moore DA, Ritmeijer K, du Cros P, Fielding K, TB-PRACTECAL team.
    Lancet Respir Med; 2024 Feb; 12(2):117-128. PubMed ID: 37980911
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
    Wirth D, Dass R, Hettle R.
    BMC Health Serv Res; 2017 Mar 08; 17(1):182. PubMed ID: 28270207
    [Abstract] [Full Text] [Related]

  • 5. Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial.
    Cevik M, Thompson LC, Upton C, Rolla VC, Malahleha M, Mmbaga B, Ngubane N, Abu Bakar Z, Rassool M, Variava E, Dawson R, Staples S, Lalloo U, Louw C, Conradie F, Eristavi M, Samoilova A, Skornyakov SN, Ntinginya NE, Haraka F, Praygod G, Mayanja-Kizza H, Caoili J, Balanag V, Dalcolmo MP, McHugh T, Hunt R, Solanki P, Bateson A, Crook AM, Fabiane S, Timm J, Sun E, Spigelman M, Sloan DJ, Gillespie SH, SimpliciTB Consortium.
    Lancet Infect Dis; 2024 Sep 08; 24(9):1003-1014. PubMed ID: 38768617
    [Abstract] [Full Text] [Related]

  • 6. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
    Schnippel K, Firnhaber C, Conradie F, Ndjeka N, Sinanovic E.
    Appl Health Econ Health Policy; 2018 Feb 08; 16(1):43-54. PubMed ID: 28980217
    [Abstract] [Full Text] [Related]

  • 7. Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria.
    Bada FO, Blok N, Okpokoro E, Dutt S, Akolo C, Dakum P, Abimiku A.
    PLoS One; 2020 Feb 08; 15(12):e0241065. PubMed ID: 33259492
    [Abstract] [Full Text] [Related]

  • 8. Availability of drugs for the treatment of multidrug-resistant/rifampicin-resistant tuberculosis in the World Health Organization European Region, October 2023.
    Otto-Knapp R, Edwards S, Kuchukhidze G, Kröger S, Häcker B, Bivol S, Yedilbayev A.
    Euro Surveill; 2024 Apr 08; 29(17):. PubMed ID: 38666403
    [Abstract] [Full Text] [Related]

  • 9. Treatment of MDR, Pre-XDR, XDR, and Rifampicin-Resistant Tuberculosis or in Case of Intolerance to at Least Rifampicin in Austria, Germany, and Switzerland.
    Otto-Knapp R, Bauer T, Brinkmann F, Feiterna-Sperling C, Friesen I, Geerdes-Fenge H, Hartmann P, Häcker B, Heyckendorf J, Kuhns M, Lange C, Maurer FP, Nienhaus A, Priwitzer M, Richter E, Salzer HJF, Schoch OD, Schönfeld N, Schaberg T.
    Respiration; 2024 Apr 08; 103(9):593-600. PubMed ID: 38810608
    [Abstract] [Full Text] [Related]

  • 10. How much should we still worry about QTc prolongation in rifampicin-resistant tuberculosis? ECG findings from TB-PRACTECAL clinical trial.
    Motta I, Cusinato M, Ludman AJ, Lachenal N, Dodd M, Soe M, Abdrasuliev T, Usmanova R, Butabekov I, Nikolaevna TZ, Liverko I, Parpieva N, Moodliar R, Solodovnikova V, Kazounis E, Nyang'wa B-T, Fielding KL, Berry C.
    Antimicrob Agents Chemother; 2024 Jul 09; 68(7):e0053624. PubMed ID: 38842323
    [Abstract] [Full Text] [Related]

  • 11. World Health Organization 2018 treatment guidelines for rifampicin-resistant tuberculosis: uncertainty, potential risks and the way forward.
    Van Deun A, Decroo T, Tahseen S, Trébucq A, Schwoebel V, Ortuno-Gutierrez N, de Jong BC, Rieder HL, Piubello A, Chiang CY.
    Int J Antimicrob Agents; 2020 Jan 09; 55(1):105822. PubMed ID: 31626907
    [Abstract] [Full Text] [Related]

  • 12. Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis.
    Xu J, Li SY, Almeida DV, Tasneen R, Barnes-Boyle K, Converse PJ, Upton AM, Mdluli K, Fotouhi N, Nuermberger EL.
    Antimicrob Agents Chemother; 2019 May 09; 63(5):. PubMed ID: 30833432
    [Abstract] [Full Text] [Related]

  • 13. Safety and Effectiveness of 3 Novel All-Oral Shortened Regimens for Rifampicin- or Multidrug-Resistant Tuberculosis in Kazakhstan.
    Rashitov M, Franke MF, Trevisi L, Bekbolatova G, Shalimova J, Eshmetov G, Bektasov S, LaHood A, Arlyapova N, Osso E, Yedilbayev A, Korotych O, Ciobanu A, Skrahina A, Mitnick CD, Seung KJ, Algozhin Y, Rich ML.
    Clin Infect Dis; 2024 Oct 15; 79(4):1046-1053. PubMed ID: 38833593
    [Abstract] [Full Text] [Related]

  • 14. Estimating the impact of a novel drug regimen for treatment of tuberculosis: a modeling analysis of projected patient outcomes and epidemiological considerations.
    Kendall EA, Malhotra S, Cook-Scalise S, Denkinger CM, Dowdy DW.
    BMC Infect Dis; 2019 Sep 09; 19(1):794. PubMed ID: 31500572
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis.
    Sweeney S, Berry C, Kazounis E, Motta I, Vassall A, Dodd M, Fielding K, Nyang'wa BT.
    PLOS Glob Public Health; 2022 Sep 09; 2(12):e0001337. PubMed ID: 36962909
    [Abstract] [Full Text] [Related]

  • 16. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis.
    Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, Solodovnikova V, Liverko I, Moodliar R, Dodd M, Ngubane N, Rassool M, McHugh TD, Spigelman M, Moore DAJ, Ritmeijer K, du Cros P, Fielding K, TB-PRACTECAL Study Collaborators.
    N Engl J Med; 2022 Dec 22; 387(25):2331-2343. PubMed ID: 36546625
    [Abstract] [Full Text] [Related]

  • 17. TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II-III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis.
    Berry C, du Cros P, Fielding K, Gajewski S, Kazounis E, McHugh TD, Merle C, Motta I, Moore DAJ, Nyang'wa BT.
    Trials; 2022 Jun 13; 23(1):484. PubMed ID: 35698158
    [Abstract] [Full Text] [Related]

  • 18. Nine months of bedaquiline, linezolid, levofloxacin, clofazimine, and cycloserine chemotherapy for rifampicin/multidrug-resistant tuberculosis: a multicenter, randomized, open-label non-inferiority trial in China.
    Song Y, Shu W, Pei Y, Du J, Wu G, Wang H, Mi F, Liu F, Ma L, Xie L, Kong Z, Wu X, Liu R, Chen H, Li H, Ge Q, Nie L, Lv Z, Huang X, Li M, Jiang M, Chen X, Cai Q, Chen W, Liu Y, Miao Y, Tang Y, Chen Y, Geng S, Zhou Q, Liu Y, Pang Y, Gao M.
    BMC Med; 2024 Sep 19; 22(1):401. PubMed ID: 39300460
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines.
    Gomez GB, Siapka M, Conradie F, Ndjeka N, Garfin AMC, Lomtadze N, Avaliani Z, Kiria N, Malhotra S, Cook-Scalise S, Juneja S, Everitt D, Spigelman M, Vassall A.
    BMJ Open; 2021 Dec 03; 11(12):e051521. PubMed ID: 34862287
    [Abstract] [Full Text] [Related]

  • 20. Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort study.
    Korotych O, Achar J, Gurbanova E, Hovhannesyan A, Lomtadze N, Ciobanu A, Skrahina A, Dravniece G, Kuksa L, Rich M, Khachatryan N, Germanovych M, Kadyrov A, Terleieva I, Akhundova I, Adenov M, Durdyeva M, Kiria N, Parpieva N, Yatskevich N, Jumayev R, Nurov R, Diktanas S, Vilc V, Migliori GB, Yedilbayev A.
    Lancet Infect Dis; 2024 Oct 03; 24(10):1151-1161. PubMed ID: 38880112
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.